Kolexia
Berger Marc Biologie médicale
Berger Marc
Biologie médicale
Hôpital Estaing
Clermont-Ferrand, France
160 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Maladie de Gaucher Leucémie myéloïde chronique BCR-ABL positive Leucémie myéloïde Leucémie myéloïde en phase chronique Leucémie chronique lymphocytaire à cellules B Splénomégalie Leucémie lymphoïde Anémie

Collaborateurs

Voir plus
Belmatoug Nadia
Belmatoug Nadia
Hôpital Necker Enfants Malades, Paris, France
Stirnemann Jerome
Stirnemann Jerome
Hôpital Jean Verdier, Bondy, France
Huguet Francoise
Huguet Francoise
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Etienne Gabriel
Etienne Gabriel
Institut Bergonié, Bordeaux, France

Industries

Voir plus
Novartis
16 collaboration(s)
Dernière en 2023
Sanofi
11 collaboration(s)
Dernière en 2023
Pfizer
10 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
British journal of haematology   03 mars 2024
BIO-TIMER: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Essai Clinique (CHU Clermont-Ferrand)   29 février 2024
Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206
65th ASH Annual Meeting Abstracts   02 novembre 2023
MPS (RaDiCo Cohort) (RaDiCo-MPS): Mucopolysaccharidosis Patients in France in the Era of Specific Therapeutics
Essai Clinique (Institut National de la Santé Et de la Recherche Médicale, France)   12 septembre 2023
Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Molecular genetics and metabolism   26 juillet 2023
Chronic Myeloid Leukemia (CML) Real-Life Database
Essai Clinique (CHU Clermont-Ferrand)   18 juillet 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Leukemia research   09 mai 2023
Freezing Does Not Alter Sperm Telomere Length despite Increasing DNA Oxidation and Fragmentation.
Genes   03 mai 2023